RNA

RNA

USD

Avidity Biosciences Inc. Common Stock

$69.830+0.050 (0.072%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$69.780

Максимум

$69.870

Минимум

$69.760

Объем

7.06M

Фундаментальные показатели компании

Рыночная капитализация

10.3B

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

5.20M

Биржа

NGM

Валюта

USD

52-недельный диапазон

Минимум $21.51Текущая $69.830Максимум $70.51

Связанные новости

PR Newswire

Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Просмотреть больше
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights
Analyst Upgrades

TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74

TD Cowen analyst Ritu Baral downgrades Avidity Biosciences from Buy to Hold and lowers the price target from $78 to $74.

Просмотреть больше
TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74
PR Newswire

Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with...

Просмотреть больше
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders
Analyst Upgrades

Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72

Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences from Buy to Neutral and lowers the price target from $75 to $72.

Просмотреть больше
Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Analyst Upgrades

RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72

RBC Capital analyst Luca Issi downgrades Avidity Biosciences from Outperform to Sector Perform and raises the price target from $61 to $72.

Просмотреть больше
RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72
PR Newswire

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avidity Biosciences, Inc. (NASDAQ: RNA)

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

Analyst Upgrades

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.